Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2020 Jul 20

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Medica 2020 Jul 20

DOI: 10.23736/S0026-4806.20.06682-3

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Vildagliptin protects hypoxia/reoxygenation-induced injury of cardiac microvascular endothelial cells

Xiaosheng FAN 1 , Yan YANG 2, Lin QI 3

1 Department of Cardiology, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, China; 2 Department of Health Examination Center, Qilu Hospital of Shandong University, Jinan, China; 3 Department of Internal Medicine, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, China


PDF


BACKGROUND: To uncover the protective role of Vildagliptin in hypoxia-reoxygenation (H/R)-induced injury of cardiac microvascular endothelial cells (CMECs) and the pharmacological mechanisms.
METHODS: H/R model was constructed in primary CMECs extracted from rats, followed by Vildagliptin treatment. Relative levels of DPP-4 and Nox-4 in CMECs were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Viability, glutathione (GSH) content, lactate dehydrogenase (LDH) release and inflammatory factor levels were examined. Western blot was conducted to detect protein levels of DPP-4, p38, p-p38 and nuclear translocation of p65. The transcriptional activity of nuclear factor-κB (NF-κB) was measured by luciferase assay.
RESULTS: H/R resulted in upregulation of DPP-4 and Nox-4, as well as increased LDH release in CMECs. In addition, GSH content and viability were declined, and the release of inflammatory factors were stimulated in H/R-induced CMECs. The abovementioned changes were relieved by Vildagliptin treatment. Vildagliptin markedly inhibited the activation of the p38/NF-κB signaling in H/R-induced CMECs.
CONCLUSIONS: Vildagliptin protects CMECs from H/R injury via inactivating the p38/NF-κB signaling.


KEY WORDS: Vildagliptin; H/R; NF-κB; Myocardial infarction; Oxidative stress

inizio pagina